WELCOME TO
ExpreS2ion Biotech
INVESTOR SITE
Financial Calendar
- 25/05/22
Annual General Meeting, 2022
- 31/05/22
Interim report, Q1 2022
- 18/08/22
Half-year report, 2022
- 17/11/22
Interim report, Q3 2022
- 09/02/23
Year-end report, 2022
Latest press releases
Scientific article about the advantageous S2-based protein secretion system ExpreS2 and a moderate-throughput research variant called FAS2FURIOUS
Non-regulatory pressrelease
Hørsholm, Denmark, May 9, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Frontiers in Bioengineering and Biotechnology published an article about the ability of S2 cells to express challenging targets.
ExpreS2ion announces final outcome of fully guaranteed rights issue of approximately SEK 73 million
Regulatory pressreleaseNOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. INSIDE…
Read more